Previous 10 | Next 10 |
TEL AVIV, Israel, May 12, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), today announced that it has closed the previously announced registered direct offering of 6,349,208 ordinary shares of the Company, at a purchase price of $1.575 per share, in a registered direct offeri...
Gainers: Tetraphase Pharmaceuticals (NASDAQ: TTPH ) +90% . More news on: Tetraphase Pharmaceuticals, Inc., ION Geophysical Corporation, Twilio Inc., Stocks on the move, , Read more ...
VBL Therapeutics ( VBLT -18.4% ) is in the red in early trade in response to its agreements with institutional investors for the direct placement of ~6.3M ordinary shares at $1.575 per share. More news on: Vascular Biogenics Ltd., Healthcare stocks news, , Stocks on the move, Read ...
TEL AVIV, Israel, May 07, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), today announced that it has entered into definitive agreements with several institutional investors for the purchase and sale of 6,349,208 ordinary shares of the Company, at a purchase price of $1.575 p...
Study was rated in the top 10% of all abstracts in this category and was selected as Poster of Distinction Data demonstrate the potential of VBL's proprietary MOSPD2 mAbs for chronic inflammatory indications, via a novel and distinct mechanism targeting monocyte migration TEL AVIV...
TEL AVIV, Israel, May 04, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that it will host a conference call and live audio ...
TEL AVIV, Israel, May 04, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT ) is pleased to announce the publication of a new manuscript demonstrating the potential of MOSPD2 antibodies for Multiple Sclerosis (MS). VBL's data offer a differentiated approach to potential treatment o...
VBL Therapeutics (NASDAQ: VBLT ) has been awarded a non-dilutive grant of up to NIS3.175M (~$0.9M) by the Israel Innovation Authority. More news on: Vascular Biogenics Ltd., Healthcare stocks news, Stocks on the move, Read more ...
TEL AVIV, Israel, April 21, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced that it has been awarded a non-dilutive grant of up to 3.175 million New Israeli Shekels (NIS) (approximately $0.9 million) by the Israel Innovation Authority (IIA). The IIA h...
TEL AVIV, Israel, April 06, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT ), announced today that it has reached a milestone event under its collaborative agreement with a world-leading European animal health company, evaluating use of VB-201 for veterinary applications. Upon rea...
News, Short Squeeze, Breakout and More Instantly...
Vascular Biogenics Ltd. Company Name:
VBLT Stock Symbol:
NASDAQ Market:
Approved Merger with Notable Labs and All Other Proposals Merger Expected to Close and Begin Trading as Combined Company Under the NTBL Ticker on Nasdaq Next Week, Subject to Effectiveness of Approved Israeli Corporate Actions MODI’IN, Israel and NEW YORK, Oct. 12, 2023 (GL...
MODI’IN, Israel and NEW YORK, Oct. 04, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (“VBL”), reminds its shareholders to vote in favor of the previously announced proposed merger (the “Merger”) with Notable Labs (“Notable”) at the annua...
Merger with Notable expected to close in mid-October, subject to shareholder approval Special shareholder meeting scheduled for October 12, 2023 MODI’IN, Israel and NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (“VBL”), today ann...